Seeing Is Believing
Currently out of the existing stock ratings of Katherine Breedis, 5 are a BUY (100%).
Analyst Katherine Breedis, carries an average stock price target met ratio of 50% that have a potential upside of 40.48% achieved within 1465 days. Previously, Katherine Breedis worked at STIFEL.
Katherine Breedis’s has documented 10 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on VYGR, Voyager Therapeutics at 28-Jul-2017.
Analyst best performing recommendations are on GILD (GILEAD SCIENCES).
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
Since 07-Jan-2026
$145
$23.9 (19.74%)
$85
3 days ago
(07-Jan-2026)
32/33 (96.97%)
$23.64 (19.48%)
1412
Buy
Since 14-Nov-2024
$140
$18.9 (15.61%)
$135
3 days ago
(07-Jan-2026)
16/18 (88.89%)
$18.64 (15.36%)
1167
Buy
Since 10-Jan-2025
$151
$29.9 (24.69%)
$135
29 days ago
(12-Dec-2025)
30/33 (90.91%)
$27.79 (22.55%)
603
Buy
Since 07-Oct-2024
$150
$28.9 (23.86%)
$140
1 months ago
(10-Dec-2025)
17/19 (89.47%)
$28.66 (23.62%)
478
Buy
Since 03-Nov-2025
$140
$18.9 (15.61%)
$145
1 months 17 days ago
(24-Nov-2025)
2/4 (50%)
$13.36 (10.55%)
73
What Year was the first public recommendation made by Katherine Breedis?